학술논문

High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy
Document Type
Article
Source
In: British Journal of Cancer. (British Journal of Cancer, 8 January 2019, 120(1):79-87)
Subject
Language
English
ISSN
15321827
00070920